Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

The surge in popularity of drugs like Ozempic, driven in part by its weight loss benefits, is contributing to a record-high ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

Not only did I not know that longtime local brewery Novo Brazil had opened a new spot in the Mission Valley Mall, but I also ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Semaglutide, the same compound that’s in Ozempic, is part of a class of medications known as glucagon-like peptide 1 (GLP-1) ...

Skye Bioscience (NASDAQ: SKYE) is a micro-cap pharmaceutical company that is striving to become the next big thing in the weight loss drug space.

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.